The occurrence of the COVID-19 pandemic has raised new uncertainties for dermatologists and their patients, importantly concerning initiation and continuation of immunosuppressants for dermatological conditions at this time. We review two phase III trials of rituximab, a chimeric CD20 monoclonal antibody, used for the treatment of pemphigus vulgaris (PV). Without specific data studying rituximab use and susceptibility of SARS-CoV-2, we hope to utilize available data in order to assist clinician decision making for rituximab in the context of the pandemic.
Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris.